DDT抗体;DDT Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human liver tissue lysate, Primary antibody: P12704(DDT Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12704(DDT Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

**Background of DDT Antibodies**

Dichlorodiphenyltrichloroethane (DDT), a synthetic organochlorine insecticide, was widely used from the 1940s to control vector-borne diseases and agricultural pests. Despite its ban in many countries due to environmental persistence and toxicity, DDT residues remain globally, accumulating in ecosystems and human tissues.

Antibodies targeting DDT or its metabolites (e.g., DDE, DDD) have been developed for environmental and biological monitoring. These antibodies are typically generated by immunizing animals with DDT-like haptens conjugated to carrier proteins, prompting an immune response. Monoclonal or polyclonal formats are used, with monoclonal antibodies offering higher specificity.

DDT antibodies enable sensitive detection via immunoassays (e.g., ELISA), replacing costly chromatography-based methods. They bind DDT metabolites, aiding in quantifying exposure levels in serum, soil, or water. Cross-reactivity with structurally similar compounds, however, can limit accuracy, necessitating careful validation.

Research also explores therapeutic applications, such as neutralizing DDT toxicity, though this remains experimental. Challenges include improving antibody stability and affinity for diverse DDT derivatives. Advances in recombinant antibody technology may enhance their utility in environmental monitoring and public health.

Overall, DDT antibodies represent critical tools for addressing legacy pollution and understanding human exposure risks in contaminated regions.